Literature DB >> 2391415

Differential sensitivity of specific and nonspecific antigen-presentation by B cells to a protein synthesis inhibitor.

T Kakiuchi1, M Watanabe, N Hozumi, H Nariuchi.   

Abstract

Specific and nonspecific Ag-presentation by B cells was examined for the sensitivity to the treatment with emetin, an irreversible protein synthesis inhibitor. For this aim, A20-HL B lymphoma cells expressing surface IgM receptors specific for TNP were used as APC. OVA and TNP-OVA were used as nonspecific and specific Ag, respectively. The treatment with emetin greatly impaired the ability of A20-HL cells to present specific Ag, but not nonspecific Ag, to 42-6A cloned T cells specific for OVA. The ability of the emetin-treated A20-HL cells to present nonspecific Ag indicates that the treated cells are able to process nonspecific Ag and to present processed Ag. Ag binding and the internalization by A20-HL cells through surface receptors were not affected by the emetin treatment. A20-HL cells took up specific Ag for stimulation of 42-6A cells in the presence of cycloheximide, a reversible protein synthesis inhibitor. These results suggest that the action of emetin is localized to the intracellular processing of specific Ag, not of nonspecific Ag. Thus, the processing pathway for specific Ag seems to be different from that for nonspecific Ag.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2391415

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Diversity in MHC class II antigen presentation.

Authors:  John H Robinson; Alexei A Delvig
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  Enhancement of antigen-presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7-1 expression.

Authors:  T Aoi; H Nakano; Y Tanaka; T Kakiuchi
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

3.  Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation.

Authors:  A Seo; F Ishikawa; H Nakano; H Nakazaki; K Kobayashi; T Kakiuchi
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

4.  Concanamycin A, a vacuolar type H(+)-ATPase inhibitor, induces cell death in activated CD8(+) CTL.

Authors:  K Togashi; T Kataoka; K Nagai
Journal:  Cytotechnology       Date:  1997-11       Impact factor: 2.058

5.  Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells.

Authors:  Hideko Torihata; Fumio Ishikawa; Yayoi Okada; Yuriko Tanaka; Tetsuya Uchida; Toru Suguro; Terutaka Kakiuchi
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

6.  Related leucine-based cytoplasmic targeting signals in invariant chain and major histocompatibility complex class II molecules control endocytic presentation of distinct determinants in a single protein.

Authors:  G Zhong; P Romagnoli; R N Germain
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

7.  Delivery of B cell receptor-internalized antigen to endosomes and class II vesicles.

Authors:  J R Drake; P Webster; J C Cambier; I Mellman
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.